Management of Locally Advanced Pancreatic Cancer

Supplemental Digital Content is available in the text Objective: The aim of this study was to investigate surgeon preferences for the management of patients with locally advanced pancreatic cancer (LAPC). Background: Select patients with LAPC may become candidates for curative resection following neoadjuvant therapy, and recent reports of survival are encouraging. Yet the optimal management approach remains unclear. Methods: An extensive electronic survey was systematically distributed by email to an international cohort of pancreas surgeons. Data collected included practice characteristics, management preferences, attitudes regarding contraindications to surgery, and 6 clinical vignettes of patients that ultimately received a margin negative resection (with detailed videos of post-neoadjuvant imaging) to assess propensity for surgical exploration if resection status is not known. Results: A total of 153 eligible responses were received from 4 continents. Median duration of practice is 12 years (interquartile range 6–20) and 77% work in a university setting. Most surgeons (86%) are considered high volume (>10 resections/yr), 33% offer a minimally-invasive approach, and 50% offer arterial resections in select patients. Most (72%) always recommend neoadjuvant chemotherapy, and 65% prefer FOLFIRINOX. Preferences for the duration of chemotherapy varied widely: 39% prefer ≥2 months, 43% prefer ≥4 months, and 11% prefer ≥6 months. Forty-one percent frequently recommend neoadjuvant radiotherapy, and 53% prefer 5 to 6 weeks of chemoradiation. The proportion of surgeons favoring exploration following neoadjuvant varied extensively across 5 vignettes of LAPC, from 14% to 53%. In a vignette of oligometastatic liver metastases, 31% would offer exploration if a favorable therapy response is observed. Conclusions: In an international cohort of pancreas surgeons, there is substantial variation in management preferences, perceived contraindications to surgery, and the propensity to consider exploration in LAPC. These results emphasize the importance of a robust and nuanced multidisciplinary discussion for each patient, and suggest an evolving concept of “resectability.”

[1]  Y. Mou,et al.  Laparoscopic pancreaticoduodenectomy for pancreatic cancer: a hope or hype? , 2020, Hepatobiliary surgery and nutrition.

[2]  B. Erickson,et al.  Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. , 2020, Annals of surgery.

[3]  J. Kleeff,et al.  Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer? , 2019, EClinicalMedicine.

[4]  J. Cameron,et al.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.

[5]  M. Ducreux,et al.  Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study , 2019, BMC Cancer.

[6]  R. J. Haas,et al.  Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation , 2019, The British journal of surgery.

[7]  W. Harmsen,et al.  Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[8]  Yuman Fong,et al.  Robotic surgery trends in general surgical oncology from the National Inpatient Sample , 2018, Surgical Endoscopy.

[9]  M. Reni,et al.  A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. , 2018, European journal of cancer.

[10]  M. Makary,et al.  Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study , 2018, Annals of surgery.

[11]  M. Makary,et al.  Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? , 2018, Annals of surgery.

[12]  T. Liang,et al.  Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. , 2018, Surgery.

[13]  F. Rocha,et al.  Surgical strategies and novel therapies for locally advanced pancreatic cancer , 2017, Journal of surgical oncology.

[14]  L. Schwartz,et al.  Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas , 2017, BMC Cancer.

[15]  J. Cameron,et al.  Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma , 2016, Annals of surgery.

[16]  J. Cameron,et al.  Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma , 2016, Clinical Cancer Research.

[17]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[18]  J. Kench,et al.  Meta‐analysis of radical resection rates and margin assessment in pancreatic cancer , 2015, The British journal of surgery.

[19]  D. Urbach Pledging to Eliminate Low-Volume Surgery. , 2015, The New England journal of medicine.

[20]  S. Hendren,et al.  Surgical Referral for Colorectal Liver Metastases: A Population-Based Survey , 2015, Annals of Surgical Oncology.

[21]  Jin He,et al.  A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the Nationwide Inpatient Sample. , 2014, Surgery.

[22]  K. Lillemoe,et al.  Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey. , 2014, Canadian journal of surgery. Journal canadien de chirurgie.

[23]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[24]  J. Cameron,et al.  Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships , 2013, Journal of Radiation Oncology.

[25]  B. Lapuyade,et al.  An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. , 2013, European journal of radiology.

[26]  K. Lillemoe,et al.  Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.

[27]  Justin B. Dimick,et al.  Hospital Volume and Operative Mortality in the Modern Era , 2013, Annals of surgery.

[28]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[29]  G. Abel,et al.  Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey , 2012, British Journal of Cancer.

[30]  N. D. Merrett,et al.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[32]  A. Shields,et al.  F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer , 2010 .

[33]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[34]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[35]  Derrick Wong,et al.  Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy , 2008, Pancreas.

[36]  N. Ahuja,et al.  What constitutes a "high-volume" hospital for pancreatic resection? , 2008, Journal of the American College of Surgeons.

[37]  M. Levy,et al.  International differences in end-of-life attitudes in the intensive care unit: results of a survey. , 2005, Archives of internal medicine.

[38]  J. Birkmeyer,et al.  Surgeon volume and operative mortality in the United States. , 2003, The New England journal of medicine.

[39]  J. Birkmeyer,et al.  Hospital Volume and Surgical Mortality in the United States , 2002 .

[40]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[41]  Jeffrey W. Clark,et al.  Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX , 2019, Annals of surgery.

[42]  Jeffrey W. Clark,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.

[43]  L. Tanoue Cancer Statistics, 2009 , 2010 .

[44]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.